The CMTA-INC Alliance is a strategic partnership between the Charcot-Marie-Tooth Association (CMTA) and the Inherited Neuropathy Consortium (INC), created to accelerate clinical research and trial readiness in Charcot-Marie-Tooth disease (CMT).
Through this alliance, CMTA is investing $1.2 million annually to sustain and expand INC’s global research infrastructure. With over 8,300 individuals enrolled across 20+ sites worldwide, INC is the clinical research engine driving CMT natural history studies, outcome measure development, biomarker validation, and new gene discovery. This work helps ensure that CMT is ready for the trials of today and the therapies of tomorrow.
CMTA’s support also funds genetic testing, researcher training, and the tools that pharmaceutical companies rely on to advance new treatments. It’s part of our commitment to every person with CMT, regardless of type.
Together, we’re closing critical gaps in clinical research and building the foundation for a future with treatments for all.
CMTA-Sponsored INC Research
Through the CMTA-INC Alliance, CMTA funds a range of projects that strengthen the clinical research foundation for CMT. These projects span natural history data collection, biomarker validation, outcome measure development, and genetic discovery. Each project contributes to the shared goal of closing diagnostic gaps, preparing for clinical trials, and accelerating the path toward effective treatments for all of CMT. Browse the CMTA-sponsored INC projects below to discover this work in action.
